Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555081 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
NCT06555081: Completed Phase 1 study, sponsored by Incyte Corporation.
NCT06555081 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 168 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (180% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06555081, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
Study Summary
This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
Primary Outcome
INCB018424 concentration in plasma.
Interventions
- DRUG Ruxolitinib IR
- DRUG Ruxolitinib XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
What the finished NCT06555081 record still lists
NCT06555081 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (180% higher).
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib IR is the first listed.
NCT06555081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06555081 about?
NCT06555081 is a clinical study titled "A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants". This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
What is the current status of trial NCT06555081?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2024-09-25. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT06555081?
The interventions under investigation include: Ruxolitinib IR (DRUG), Ruxolitinib XR (DRUG).
Who is sponsoring clinical trial NCT06555081?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06555081's enrollment target sits among peer trials
168 326th of 2000 higher than 1,671 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI